KRW 5130.0
(-1.35%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -17.23 Billion KRW | -164.52% |
2022 | 26.71 Billion KRW | -26.1% |
2021 | 36.15 Billion KRW | 188.13% |
2020 | -41.01 Billion KRW | -329.02% |
2019 | -9.56 Billion KRW | 76.63% |
2018 | -40.91 Billion KRW | -95.2% |
2017 | -20.96 Billion KRW | -1245.01% |
2016 | -1.55 Billion KRW | -3.07% |
2015 | -1.51 Billion KRW | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | 1.76 Billion KRW | 144.85% |
2024 Q1 | -3.94 Billion KRW | 29.42% |
2023 Q3 | -6.31 Billion KRW | -961.68% |
2023 Q1 | -4.73 Billion KRW | 80.94% |
2023 FY | -17.23 Billion KRW | -164.52% |
2023 Q4 | -5.58 Billion KRW | 11.53% |
2023 Q2 | -595.03 Million KRW | 87.44% |
2022 Q1 | 34.93 Billion KRW | 212.42% |
2022 FY | 26.71 Billion KRW | -26.1% |
2022 Q4 | -24.85 Billion KRW | -970.95% |
2022 Q3 | 2.85 Billion KRW | -79.29% |
2022 Q2 | 13.77 Billion KRW | -60.56% |
2021 Q1 | 5.65 Billion KRW | 72.21% |
2021 Q2 | -563.04 Million KRW | -109.96% |
2021 Q3 | 19.87 Billion KRW | 3630.23% |
2021 FY | 36.15 Billion KRW | 188.13% |
2021 Q4 | 11.18 Billion KRW | -43.74% |
2020 Q4 | 3.28 Billion KRW | 111.84% |
2020 Q2 | -14.51 Billion KRW | -607.71% |
2020 Q1 | -2.05 Billion KRW | 58.09% |
2020 FY | -41.01 Billion KRW | -329.02% |
2020 Q3 | -27.74 Billion KRW | -91.18% |
2019 Q3 | -1.69 Billion KRW | 2.78% |
2019 FY | -9.56 Billion KRW | 76.63% |
2019 Q4 | -4.89 Billion KRW | -188.74% |
2019 Q2 | -1.74 Billion KRW | -41.33% |
2019 Q1 | -1.23 Billion KRW | -116.71% |
2018 Q3 | -38.26 Billion KRW | 0.0% |
2018 Q4 | -569.02 Million KRW | 98.51% |
2018 FY | -40.91 Billion KRW | -95.2% |
2017 FY | -20.96 Billion KRW | -1245.01% |
2016 FY | -1.55 Billion KRW | -3.07% |
2015 FY | -1.51 Billion KRW | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 116.43 Billion KRW | 114.805% |
InBody Co.,Ltd | 36.72 Billion KRW | 146.942% |
Curexo Inc. | -4.85 Billion KRW | -254.988% |
Seegene, Inc. | 669.01 Million KRW | 2676.679% |
i-SENS, Inc. | 3.7 Billion KRW | 564.761% |
Ray Co., Ltd. | -2.14 Billion KRW | -703.156% |
Gencurix Inc. | -19.26 Billion KRW | 10.497% |
L&C Bio Co., Ltd | 48.36 Billion KRW | 135.645% |